NCT04597801View on ClinicalTrials.gov

Comparison of Fluorescein-INtra-VItal Microscopy Versus Conventional Frozen Section Diagnosis for intraOperative Histopathological Evaluation

PHASE2CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

December 30, 2020

Primary Completion Date

June 17, 2022

Study Completion Date

August 3, 2022

Conditions
Intracranial Tumor
Interventions
DRUG

Alcon

Fluorescein sodium is administered intravenously with a bolus injection of 5 mg per kg of bodyweight 20-40 minutes prior to the planned tumor resection.

Trial Locations (3)

68167

Universitätsklinikum Mannheim, Mannheim

81675

Technische Universität München, Klinik und Poliklinik für Neurochirurgie, München

93053

Universitätsklinikum Regensburg, Regensburg

Sponsors

Collaborators (1)

Carl Zeiss Meditec AG
All Listed Sponsors
collaborator

Carl Zeiss Meditec AG

INDUSTRY

lead

Technical University of Munich

OTHER

NCT04597801 - Comparison of Fluorescein-INtra-VItal Microscopy Versus Conventional Frozen Section Diagnosis for intraOperative Histopathological Evaluation | Biotech Hunter | Biotech Hunter